|
|
Rosa Marina Melillo, Maria Domenica Castellone, Valentina Guarino, Valentina De Falco, Anna Maria Cirafici, Giuliana Salvatore, Fiorina Caiazzo, Fulvio Basolo, Riccardo Giannini, Mogens Kruhoffer, Torben Orntoft, Alfredo Fusco, Massimo Santoro
J Clin Invest. 2005;
115(4):1068
doi:10.1172/JCI22758
Abstract |
Full text
| PDF
| Supplemental material
I
n papillary thyroid carcinomas (PTCs), rearrangements of the RET receptor (RET/PTC) and activating mutations in the BRAF or RAS oncogenes are mutually exclusive. Here we show that the 3 proteins function along a linear oncogenic signaling cascade in which RET/PTC induces RAS-dependent BRAF activation and RAS- and BRAF-dependent ERK activation. Adoptive activation of the RET/PTC-RAS-BRAF axis induced cell proliferation and Matrigel invasion of thyroid follicular cells. Gene expression profiling revealed that the 3 oncogenes activate a common transcriptional program in thyroid cells that includes upregulation of the CXCL1 and CXCL10 chemokines, which in turn stimulate proliferation and invasion. Thus, motile and mitogenic properties are intrinsic to transformed thyroid cells and are governed by an epistatic oncogenic signaling cascade.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(44)
| Title and authors |
Publication |
Year |
RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint
V. Marotta, A. Guerra, M. R. Sapio, M. Vitale
|
European Journal of Endocrinology
|
2011 |
The RET p.G533C Mutation Confers Predisposition to Multiple Endocrine Neoplasia Type 2A in a Brazilian Kindred and Is Able to Induce a Malignant PhenotypeIn VitroandIn Vivo
Mariana N.L. Oliveira, Jefferson P. Hemerly, André U. Bastos, Rosana Tamanaha, Flavia R.M. Latini, Cléber P. Camacho, Anelise Impellizzeri, Rui M.B. Maciel, Janete M. Cerutti
|
Thyroid
|
2011 |
BRAFV600E mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas
C. Durante, G. Tallini, E. Puxeddu, M. Sponziello, S. Moretti, C. Ligorio, A. Cavaliere, K. J. Rhoden, A. Verrienti, M. Maranghi, L. Giacomelli, D. Russo, S. Filetti
|
European Journal of Endocrinology
|
2011 |
CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas
Liborio Torregrossa, Riccardo Giannini, Nicla Borrelli, Elisa Sensi, Rosa Marina Melillo, Pietro Leocata, Gabriele Materazzi, Paolo Miccoli, Massimo Santoro, Fulvio Basolo
|
Mod Pathol
|
2011 |
MicroRNA binding site polymorphisms as biomarkers of cancer risk
Cory Pelletier, Joanne B Weidhaas
|
Expert Rev Mol Diagn
|
2010 |
Sorafenib: Rays of Hope in Thyroid Cancer
Leonidas H. Duntas, Renato Bernardini
|
Thyroid
|
2010 |
AreRET/PTCRearrangements in Benign Thyroid Nodules of Biological Significance?
Vincenzo Marotta, Anna Guerra, Maria Rosaria Sapio, Elisabetta Campanile, Manuela Motta, Gianfranco Fenzi, Guido Rossi, Mario Vitale
|
Thyroid
|
2010 |
New targeted molecular therapies for dedifferentiated thyroid cancer.
Alessandro Antonelli, Clodoveo Ferri, Silvia Martina Ferrari, Marco Sebastiani, Michele Colaci, Ilaria Ruffilli, Poupak Fallahi
|
Journal of Oncology
|
2010 |
Mast cells have a protumorigenic role in human thyroid cancer
R M Melillo, V Guarino, E Avilla, M R Galdiero, F Liotti, N Prevete, F W Rossi, F Basolo, C Ugolini, A de Paulis, M Santoro, G Marone
|
Oncogene
|
2010 |
Thyroid tumors: novel insights from proteomic studies
Giuseppe Damante, Andrea Scaloni, Gianluca Tell
|
Expert Rev Proteomics
|
2009 |
|